Open Access Macedonian Journal of Medical Sciences.
http://dx.doi.org/10.3889/oamjms.2015.053
Clinical Science
|
|
The Effect of Combined Therapy
ICS/LABA and ICS/LABA plus Montelukast in Patients with Uncontrolled Severe
Persistent Asthma Based on the Serum IL-13 and FEV1
Elena Jovanovska Janeva1, Zlatica Goseva1,
Angjelko Gjorchev1, Angela Debreslioska1, Mirko
Spiroski2, Beti Zafirova3, Magdalena Genadieva
Dimitrova4
1University Clinic of Pulmonology and Allergology, Faculty of
Medicine, Ss Cyril and Methodius University of Skopje, Skopje, Republic of
Macedonia; 2Institute of Immunobiology and Human Genetics,
Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje,
Republic of Macedonia; 3Institute of Epidemiology and
Biostatistics, Faculty of Medicine, Ss Cyril and Methodius University of
Skopje, Skopje, Republic of Macedonia; 4University Clinic of
Gastroenterohepatology, Faculty of Medicine, Ss Cyril and Methodius
University of Skopje, Skopje, Republic of Macedonia
BACKGROUND: IL-13 is one of many cytokines responsible for the
chronic inflammation of asthma.
AIM: The aim of this study was to determine the effect of combined
therapy ICS/LABA and ICS/LABA plus Montelukast in patients with uncontrolled
severe persistent asthma by analyzing of serum IL-13 and FEV1 before the
treatment and after 6 months of therapy.
MATERIAL AND METHODS: In study we included two groups. First group
with 27 patients were treated with ICS/LABA. Second group with 29 patients
were treated with ICS/LABA plus Montelukast. In each of them were measured
serum IL-13 levels by the ELISA method and FEV1 before and after 6 months of
treatment. Results were statistically analyzed according to the Wilcoxon
Pairs Test and T-test.
RESULTS: The obtained results in both groups showed that the serum
IL-13 before the start of therapy were much higher and after 6 months of
treatment significantly reduces their value, which in the second group were
more expressed. The difference in the average value of FEV1 in both groups
before and after therapy was statistically significant.
CONCLUSION: Treatment with ICS/LABA plus Montelukast proved superior
compared to therapy of ICS/LABA in patients with uncontrolled severe
persistent asthma and allows achievement of well controlled of asthma with
subjective clinical improvement.
..................
Citation: Jovanovska Janeva E, Goseva Z,
Gjorchev A, Debreslioska A, Spiroski M, Zafirova B, Genadieva Dimitrova M.
The Effect of Combined Therapy ICS/LABA and ICS/LABA plus Montelukast in
Patients with Uncontrolled Severe Persistent Asthma Based on the Serum IL-13
and FEV1. OA Maced J Med Sci. http://dx.doi.org/10.3889/oamjms.2015.053
Key words: asthma; IL-13; FEV1; ICS/LABA; Montelukast.
*Correspondence: Elena Jovanovska Janeva, MD, MSc. University Clinic
of Pulmonology and Allergology, Faculty of Medicine, Ss Cyril and Methodius
University of Skopje, Skopje, Republic of Macedonia. E-mail: eli.janeva@yahoo.com
Received: 29-Mar-2015; Revised: 28-Apr-2015; Accepted: 29-Apr-2015; Online
first: 07-May-2015
Copyright: © 2015 Elena Jovanovska Janeva, Zlatica Goseva, Angjelko
Gjorchev, Angela Debreslioska, Mirko Spiroski, Beti Zafirova, Magdalena
Genadieva Dimitrova. This is an open access article distributed under the
terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Competing Interests: The authors have declared that no competing
interests exist.
|
<
Previous
|
Next Article >
Table of contents
This Article
(free)
Full text (pdf)
Full text OnlineFirst (pdf)
Google Scholar
-
Jovanovska Janeva E
-
Goseva Z
-
Gjorchev A
-
Debreslioska A
-
Spiroski M
-
Zafirova B
-
Genadieva Dimitrova M
PubMed
- Jovanovska Janeva E
- Goseva Z
- Gjorchev A
- Debreslioska A
- Spiroski M
- Zafirova B
- Genadieva Dimitrova M
|